CHAMBON P, WEILL JD, MANDEL P (1963) Nicotinamide mononucleotide activation of new DNA-dependent polyadenylic acid synthesizing nuclear enzyme. Biochem Biophys Res Commun 11:39–43. https://doi.org/10.1016/0006-291x(63)90024-x

Article  CAS  PubMed  Google Scholar 

Chen A (2011) PARP inhibitors: its role in treatment of cancer. Chin J Cancer 30:463–471. https://doi.org/10.5732/cjc.011.10111

Article  CAS  PubMed  PubMed Central  Google Scholar 

Li W, Wang F, Song G, Yu Q, Du R, Xu P (2023) PARP-1: a critical regulator in radioprotection and radiotherapy-mechanisms, challenges, and therapeutic opportunities. Front Pharmacol 14:1198948. https://doi.org/10.3389/fphar.2023.1198948

Article  CAS  PubMed  PubMed Central  Google Scholar 

Shall S, de Murcia G (2000) Poly(ADP-ribose) polymerase-1: what have we learned from the deficient mouse model? Mutat Res 460:1–15. https://doi.org/10.1016/s0921-8777(00)00016-1

Article  CAS  PubMed  Google Scholar 

Virag L, Szabo C (2002) The therapeutic potential of poly(ADP-ribose) polymerase inhibitors. Pharmacol Rev 54:375–429. https://doi.org/10.1124/pr.54.3.375

Article  CAS  PubMed  Google Scholar 

Masutani M, Nozaki T, Nakamoto K, Nakagama H, Suzuki H, Kusuoka O, Tsutsumi M, Sugimura T (2000) The response of parp knockout mice against DNA damaging agents. Mutat Res 462:159–166. https://doi.org/10.1016/s1383-5742(00)00033-8

Article  CAS  PubMed  Google Scholar 

Herrmann GK, Yin YW (2023) The role of poly(ADP-ribose) polymerase 1 in Nuclear and mitochondrial base excision repair. Biomolecules 13:1195. https://doi.org/10.3390/biom13081195

Article  CAS  PubMed  PubMed Central  Google Scholar 

Barazzuol L, Jena R, Burnet NG, Meira LB, Jeynes JCG, Kirkby KJ, Kirkby NF (2013) Evaluation of poly (ADP-ribose) polymerase inhibitor ABT-888 combined with radiotherapy and temozolomide in glioblastoma. Radiat Oncol 8:65–65. https://doi.org/10.1186/1748-717X-8-65

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tisdale MJ (1987) Antitumor imidazotetrazines–XV. Role of guanine O6 alkylation in the mechanism of cytotoxicity of imidazotetrazinones. Biochem Pharmacol 36:457–462. https://doi.org/10.1016/0006-2952(87)90351-0

Article  CAS  PubMed  Google Scholar 

Denny BJ, Wheelhouse RT, Stevens MF, Tsang LL, Slack JA (1994) NMR and molecular modeling investigation of the mechanism of activation of the antitumor drug temozolomide and its interaction with DNA. Biochemistry 33:9045–9051. https://doi.org/10.1021/bi00197a003

Article  CAS  PubMed  Google Scholar 

Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, Kros JM, Hainfellner JA, Mason W, Mariani L et al (2005) MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352:997–1003. 352/10/997 [pii]

Article  CAS  PubMed  Google Scholar 

Yuan AL, Ricks CB, Bohm AK, Lun X, Maxwell L, Safdar S, Bukhari S, Gerber A, Sayeed W, Bering EA et al (2018) ABT-888 restores sensitivity in temozolomide resistant glioma cells and xenografts. PLoS ONE 13:e0202860. https://doi.org/10.1371/journal.pone.0202860

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wu S, Li X, Gao F, de Groot JF, Koul D, Yung WKA (2021) PARP-mediated PARylation of MGMT is critical to promote repair of temozolomide-induced O6-methylguanine DNA damage in glioblastoma. Neuro Oncol 23:920–931. https://doi.org/10.1093/neuonc/noab003

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tentori L, Portarena I, Torino F, Scerrati M, Navarra P, Graziani G (2002) Poly(ADP-ribose) polymerase inhibitor increases growth inhibition and reduces G(2)/M cell accumulation induced by temozolomide in malignant glioma cells. Glia 40:44–54. https://doi.org/10.1002/glia.10113

Article  PubMed  Google Scholar 

Barazzuol L, Jena R, Burnet NG, Jeynes JCG, Merchant MJ, Kirkby KJ, Kirkby NF (2012) In vitro evaluation of combined temozolomide and radiotherapy using X rays and high-linear energy transfer radiation for glioblastoma. Radiat Res 177:651–662. https://doi.org/10.1667/rr2803.1

Article  CAS  PubMed  Google Scholar 

Lesueur P, Chevalier F, Austry J, Waissi W, Burckel H, Noel G, Habrand J, Saintigny Y, Joly F (2017) Poly-(ADP-ribose)-polymerase inhibitors as radiosensitizers: a systematic review of pre-clinical and clinical human studies. Oncotarget 8:69105–69124. https://doi.org/10.18632/oncotarget.19079

Article  PubMed  PubMed Central  Google Scholar 

Bhamidipati D, Haro-Silerio JI, Yap TA, Ngoi N (2023) PARP inhibitors: enhancing efficacy through rational combinations. Br J Cancer. https://doi.org/10.1038/s41416-023-02326-7

Article  PubMed  PubMed Central  Google Scholar 

Coleman RL, Fleming GF, Brady MF, Swisher EM, Steffensen KD, Friedlander M, Okamoto A, Moore KN, Efrat Ben-Baruch N, Werner TL et al (2019) Veliparib with First-Line Chemotherapy and as maintenance therapy in Ovarian Cancer. N Engl J Med 381:2403–2415. https://doi.org/10.1056/NEJMoa1909707

Article  CAS  PubMed  PubMed Central  Google Scholar 

Han HS, Dieras V, Robson M, Palacova M, Marcom PK, Jager A, Bondarenko I, Citrin D, Campone M, Telli ML et al (2018) Veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in patients with BRCA1/2 locally recurrent/metastatic Breast cancer: randomized phase II study. Ann Oncol 29:154–161. https://doi.org/10.1093/annonc/mdx505

Article  CAS  PubMed  Google Scholar 

Dieras V, Han HS, Kaufman B, Wildiers H, Friedlander M, Ayoub J, Puhalla SL, Bondarenko I, Campone M, Jakobsen EH et al (2020) Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced Breast cancer (BROCADE3): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 21:1269–1282. https://doi.org/10.1016/S1470-2045(20)30447-2

Article  CAS  PubMed  Google Scholar 

Clarke JM, Patel JD, Robert F, Kio EA, Thara E, Ross Camidge D, Dunbar M, Nuthalapati S, Dinh MH, Bach BA (2021) Veliparib and Nivolumab in combination with platinum doublet chemotherapy in patients with metastatic or advanced non-small cell Lung cancer: a phase 1 dose escalation study. Lung Cancer 161:180–188. https://doi.org/10.1016/j.lungcan.2021.09.004

Article  CAS  PubMed  Google Scholar 

Tuli R, Shiao SL, Nissen N, Tighiouart M, Kim S, Osipov A, Bryant M, Ristow L, Placencio-Hickok V, Hoffman D et al (2019) A phase 1 study of veliparib, a PARP-1/2 inhibitor, with gemcitabine and radiotherapy in locally advanced Pancreatic cancer. EBioMedicine 40:375–381. https://doi.org/10.1016/j.ebiom.2018.12.060

Article  PubMed  PubMed Central  Google Scholar 

Czito BG, Deming DA, Jameson GS, Mulcahy MF, Vaghefi H, Dudley MW, Holen KD, DeLuca A, Mittapalli RK, Munasinghe W et al (2017) Safety and tolerability of veliparib combined with capecitabine plus radiotherapy in patients with locally advanced rectal cancer: a phase 1b study. Lancet Gastroenterol Hepatol 2:418–426. https://doi.org/10.1016/S2468-1253(17)30012-2

Article  PubMed  Google Scholar 

Donawho CK, Luo Y, Luo Y, Penning TD, Bauch JL, Bouska JJ, Bontcheva-Diaz VD, Cox BF, DeWeese TL, Dillehay LE et al (2007) ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical Tumor models. Clin Cancer Res 13:2728–2737. https://doi.org/10.1158/1078-0432.CCR-06-3039

Article  CAS  PubMed  Google Scholar 

Kummar S, Kinders R, Gutierrez ME, Rubinstein L, Parchment RE, Phillips LR, Ji J, Monks A, Low JA, Chen A et al (2009) Phase 0 clinical trial of the poly (ADP-ribose) polymerase inhibitor ABT-888 in patients with advanced malignancies. J Clin Oncol 27:2705–2711. https://doi.org/10.1200/JCO.2008.19.7681

Article  CAS  PubMed  PubMed Central  Google Scholar 

Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987–996. 352/10/987 [pii]

Article  CAS  PubMed  Google Scholar 

Malanga M, Althaus FR (2005) The role of poly(ADP-ribose) in the DNA damage signaling network. Biochem Cell Biol 83:354–364. https://doi.org/10.1139/o05-038

Article  CAS  PubMed  Google Scholar 

Dantzer F, Schreiber V, Niedergang C, Trucco C, Flatter E, De La Rubia G, Oliver J, Rolli V, Menissier-de Murcia J, de Murcia G (1999) Involvement of poly(ADP-ribose) polymerase in base excision repair. Biochimie 81:69–75. https://doi.org/10.1016/s0300-9084(99)80040-6

Article  CAS  PubMed  Google Scholar 

Curtin NJ, Wang L, Yiakouvaki A, Kyle S, Arris CA, Canan-Koch S, Webber SE, Durkacz BW, Calvert HA, Hostomsky Z et al (2004) Novel poly(ADP-ribose) polymerase-1 inhibitor, AG14361, restores sensitivity to temozolomide in mismatch repair-deficient cells. Clin Cancer Res 10:881–889. https://doi.org/10.1158/1078-0432.ccr-1144-3

Article  CAS  PubMed  Google Scholar 

Wang C, Li J (2021) Haematologic toxicities with PARP inhibitors in cancer patients: an uptodate metaanalysis of 29 randomized controlled trials. J Clin Pharm Ther 46:571–584. https://doi.org/10.1111/jcpt.13349

Article  CAS  PubMed  Google Scholar 

Farres J, Llacuna L, Martin-Caballero J, Martinez C, Lozano JJ, Ampurdanes C, Lopez-Contreras AJ, Florensa L, Navarro J, Ottina E et al (2015) PARP-2 sustains erythropoiesis in mice by limiting replicative stress in erythroid progenitors. Cell Death Differ 22:1144–1157. https://doi.org/10.1038/cdd.2014.202